Search Results - Delaloge, S.

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study

    First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study by Bergh, J., Bondarenko, I., Lichinitser, M., Liljegren, A., Greil, R., Voytko, N., Makhson, A., Cortes, J., Lortholary, A., Bischoff, J., Chan, Arlene, Delaloge, S., Huang, X., Kern, K., Giorgetti, C.

    Published 2012
    Get full text
  2. 2
    A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)

    A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4) by Martín, M., Chan, Arlene, Dirix, L., O'Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., Ruiz Borrego, M., Khan, Q., Beck, J., Ramos Vázquez, M., Urban, P., Goteti, S., Di Tomaso, E., Massacesi, C., Delaloge, S.

    Published 2017
    Get full text
  3. 3
    Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 tria... by Chan, Arlene, Delaloge, S., Holmes, F., Moy, B., Iwata, H., Harvey, V., Robert, N., Silovski, T., Gokmen, E., von Minckwitz, G., Ejlertsen, B., Chia, S., Mansi, J., Barrios, C., Gnant, M., Buyse, M., Gore, I., Smith, J., Harker, G., Masuda, N., Petrakova, K., Zotano, A., Iannotti, N., Rodriguez, G., Tassone, P., Wong, A., Bryce, R., Ye, Y., Yao, B., Martin, M.

    Published 2016
    Get full text
  4. 4
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial by Martin, M., Holmes, F., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S., Mansi, J., Barrios, C., Gnant, M., Tomaševic, Z., Denduluri, N., Šeparovic, R., Gokmen, E., Bashford, A., Ruiz Borrego, M., Kim, S., Jakobsen, E., Ciceniene, A., Inoue, K., Overkamp, F., Heijns, J., Armstrong, A., Link, J., Joy, A., Bryce, R., Wong, A., Moran, S., Yao, B., Xu, F., Auerbach, A., Buyse, M., Chan, Arlene, ExteNET Study Group

    Published 2017
    Get full text

Search Tools: